GoodRx Holdings (GDRX) Accumulated Expenses (2019 - 2026)

GoodRx Holdings' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $83.7 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 7.93% year-over-year to $83.7 million; the TTM figure through Mar 2026 stood at $83.7 million (up 7.93% YoY), while the FY2025 annual figure was $86.7 million, up 4.05% from the prior year.
• Accumulated Expenses came in at $83.7 million for Q1 2026 at GoodRx Holdings, down from $86.7 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $143.4 million in Q3 2025 to a low of $33.8 million in Q1 2022.
• A 5-year average of $74.0 million and a median of $73.2 million in 2024 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 206.74% in 2022 and fell as far as 3.24% in 2022.
• GoodRx Holdings' Accumulated Expenses stood at $47.5 million in 2022, then soared by 50.09% to $71.3 million in 2023, then grew by 16.83% to $83.3 million in 2024, then climbed by 4.05% to $86.7 million in 2025, then declined by 3.44% to $83.7 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $83.7 million, $86.7 million, and $143.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison